CDEK
← All drugs Report issue

terazosin

Trade name: hytrin

Small moleculeapproved

Approved

Aug 7, 1987

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. — NCATS

Clinical trial activity

24 trials · 39 clinical orgs · 18 marketing orgs

Phase 1
6
Phase 2
9
Phase 3
4
Phase 4
6

Earliest trial started Aug 1, 1998 (NCT02244255)

Timeline

1980s

  1. Aug 7, 1987

    Abbott — Earliest FDA Approval

  2. Aug 7, 1987

    Abbott — NDA Organization

1990s

  1. Mar 30, 1998

    Sandoz — Marketing Organization

  2. Mar 30, 1998

    Apnar Pharma — Marketing Organization

  3. Mar 30, 1998

    Senores Pharms — Marketing Organization

  4. Dec 31, 1998

    Novartis — Marketing Organization

  5. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Feb 11, 2000

    Mylan — Marketing Organization

  2. Feb 11, 2000

    PHARMOBEDIENT — Marketing Organization

  3. Apr 21, 2000

    Teva — Marketing Organization

  4. Apr 28, 2000

    Chartwell Pharmaceuticals — Marketing Organization

  5. Jul 28, 2000

    Beximco — Marketing Organization

  6. Jul 28, 2000

    Bionpharma Inc — Marketing Organization

  7. Jan 30, 2001

    Heritage Pharma — Marketing Organization

  8. Apr 12, 2001

    Apotex — Marketing Organization

  9. Apr 12, 2001

    Hikma — Marketing Organization

  10. Aug 22, 2002

    Ranbaxy — Marketing Organization

  11. Dec 20, 2004

    Jubilant Innovation Ltd. — Marketing Organization

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jul 29, 2024

    Novitium Pharma — Marketing Organization

  2. May 12, 2025

    Ajanta Pharma Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedAug 7, 1987

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
Mol. weight
459.93 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
  • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
  • a 45975
  • abbott-45975
  • abbott-45975
  • adecur
  • apo-terazosin
  • benph
  • deflox
  • dysalfa
  • flotrin
  • heitrin
  • hexal brand of terazosin hydrochloride
  • hytrin
  • hytrin
  • hytrin
  • hytrin
  • hytrin
  • hytrin bph
  • hytrin bph
  • hytrin bph
  • hytrine
  • magnurol
  • novo-terazosin
  • nu-terazosin
  • pms-terazosin
  • ratio-terazosin
  • sutif
  • tazusin
  • terazoflo
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosin
  • terazosina
  • terazosina
  • terazosina alter
  • terazosina kern
  • terazosina qualix
  • terazosin azu
  • terazosine
  • terazosine
  • terazosine
  • terazosine
  • térazosine
  • térazosine
  • terazosin hcl
  • terazosin hcl
  • terazosin hcl
  • terazosin hexal
  • terazosin hydrochloride
  • terazosin hydrochloride
  • terazosin hydrochloride
  • terazosin hydrochloride anhydrous
  • terazosin hydrochloride anhydrous
  • terazosin hydrochloride hydrate
  • terazosin hydrochloride hydrate
  • terazosin hydrochloride hydrate
  • terazosin, monohydrochloride, dihydrate
  • terazosinum
  • terazosinum
  • zayasel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07288450Phase 1/Phase 2 (Phase 2)Sep 1, 2026University of Iowa
NCT07224269Early Phase 1 (Phase 1)Nov 17, 2025University of Iowa
NCT07207057Phase 3Sep 12, 2025Cure Parkinson's Trust, Medical Research Council, Michael J. Fox Foundation for Parkinson's Research, National Institute for Health Research, United Kingdom, Newcastle University, University of London, Van Andel Research Institute
NCT06966804Phase 3Jun 1, 2025Penang Medical College
NCT05855577Phase 4Dec 31, 2023I.R.C.C.S. Fondazione Santa Lucia
NCT05109364Phase 2Nov 1, 2021Cedars-Sinai Medical Center
NCT04760860Phase 1/Phase 2 (Phase 2)Oct 31, 2021University of Iowa
NCT04551040Phase 1Nov 1, 2020Michael J. Fox Foundation for Parkinson's Research, University of Iowa
NCT04386317Phase 2Jul 1, 2020Cedars-Sinai Medical Center
NCT03905811Phase 1/Phase 2 (Phase 2)May 31, 2019University of Iowa
NCT03195673Phase 2Mar 2, 2018Capital Medical University
NCT01508637N/AJan 1, 2012Environmental Protection Agency, National Institute of Environmental Health Sciences (NIEHS), University of Washington
NCT01530243Phase 2/Phase 3 (Phase 3)Jan 1, 2012Urmia University of Medical Sciences
NCT02046395Phase 4Jan 1, 2012Tulane University
NCT01366664Phase 1Apr 1, 2011Johnson and Johnson
NCT00438113Phase 4Dec 1, 2009Dalhousie University, Government of Canada, Nova Scotia Health Research Foundation
NCT00687388Phase 4May 1, 2008Sungkyunkwan University, The Korean Urological Association
NCT00700583N/AMay 1, 2008Seoul National University
NCT00449683Phase 4Mar 1, 2007Brain & Behavior Research Foundation, Thomas Jefferson University
NCT00693199N/AJul 1, 2006Anhui Medical University, Peking University, University of Science and Technology of China
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (39)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of IowaAcademic/Hospital5522019
Cedars-Sinai Medical CenterAcademic/Hospital2212020
Michael J. Fox Foundation for Parkinson's ResearchAcademic/Hospital2022020
Thomas Jefferson UniversityAcademic/Hospital2222005
Anhui Medical UniversityAcademic/Hospital1112006
Boehringer IngelheimFor profit1111998
Brain & Behavior Research FoundationAcademic/Hospital1012007
Capital Medical UniversityAcademic/Hospital1112018
Centers for Disease Control and Prevention (CDC)Government1011999
Chinese University of Hong KongAcademic/Hospital1012005
Columbia UniversityAcademic/Hospital1011999
Cure Parkinson's TrustAcademic/Hospital1012025
Dalhousie UniversityAcademic/Hospital1012009
Environmental Protection AgencyGovernment1012012
Government of CanadaGovernment1112009
Government of Hong KongGovernment1112005
I.R.C.C.S. Fondazione Santa LuciaAcademic/Hospital1112023
Johnson and JohnsonFor profit1112011
Medical Research CouncilGovernment1012025
National Eye Institute (NEI)Government1011999
39 organizations
Page 1 / 2

Marketing (22)

OrganizationOrg typeRelationshipDate
AbbottFor profitNDAAug 7, 1987
Ajanta Pharma LtdFor profitMKTGMay 12, 2025
Apnar PharmaFor profitMKTGMar 30, 1998
ApotexFor profitMKTGApr 12, 2001
BeximcoFor profitMKTGJul 28, 2000
Bionpharma IncFor profitMKTGJul 28, 2000
Chartwell PharmaceuticalsFor profitMKTGApr 28, 2000
Heritage PharmaFor profitSYNJan 30, 2001
Heritage PharmaFor profitMKTGJan 30, 2001
HikmaFor profitMKTGApr 12, 2001
Jubilant Innovation Ltd.For profitMKTGDec 20, 2004
MylanFor profitMKTGFeb 11, 2000
MylanFor profitSYNDec 1, 2000
MylanFor profitSYNFeb 11, 2000
NovartisFor profitMKTGDec 31, 1998
Novitium PharmaFor profitMKTGJul 29, 2024
PHARMOBEDIENTFor profitMKTGFeb 11, 2000
RanbaxyFor profitMKTGAug 22, 2002
SandozFor profitMKTGMar 30, 1998
Senores PharmsFor profitMKTGMar 30, 1998
TevaFor profitMKTGApr 21, 2000
TevaFor profitSYNMay 18, 2000